跳至主要内容
临床试验/NCT00122252
NCT00122252终止不适用

Biological Imaging for Optimising CTV and GTV Contouring in Prostate Cancer to Improve the Possibilities for IMRT Dose Escalation

Alberta Health services1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2004年5月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
20
试验地点
1

研究概览

简要总结

The clinical outcome after external beam irradiation for prostate cancer is disappointing in the advanced tumor stages. There are indications that an increase in radiation dose to the tumor will improve outcome significantly, especially to the biologically active tumour parts within the cancer area. Until recently no imaging equipment was available to define both the anatomic and biologically active tumor parts. Now, at the Center for Biological Imaging and Adaptive Radiotherapy, equipment is at hand that will be able to visualise the areas mentioned above. When combining the data of these imaging modalities it might be possible to create an optimised irradiation plan. This study is a planning study in which, on 15 patients, the different anatomical and biological imaging data per patient will be evaluated, matched and finally a theoretical improved irradiation treatment plan will be made. This research complies with the current opinion on radiation development. Progress in functional imaging is likely to provide the tools required for individualised risk-adapted radiotherapy.

详细描述

Proposal:

To investigate the possibilities to improve Clinical Target Volume (CTV) and Gross Tumour Volume (GTV) delineation by using the latest biological imaging modalities on 15 patients with prostate cancer. Our ultimate goal is to set new GTV and CTV definitions and redefine the choice of irradiation margins in Intensity Modulated RadioTherapy (IMRT) for prostate cancer. Furthermore, try to translate the functional imaging data into a Tomotherapy IMRT plan.

Rationale:

Treatment results after standard dose external beam irradiation of locally advanced prostate cancer are insufficient. According to RTOG-8531, RTOG-8610 and EORTC series on T1 to T4 tumours, 5-year overall survival ranges 60 - 73% and 5-year disease free survival ranges 15 - 67%.

Local control can be enhanced by adjuvant androgen suppression, the 5-year disease free survival increases significantly to 36 - 89%. Unfortunately, androgen suppression significantly deteriorates quality of life.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
Male
接受健康志愿者

入选标准

  • Histologically proven prostate adenocarcinoma

排除标准

  • Previous treatment for prostate cancer
  • Contraindications to magnetic resonance imaging (MRI)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Biological Imaging for Optimising Clinical Target... | 临床试验